InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,250.54
(
0.37%
)
Post# of 252187
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119839
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 242141

Tuesday, 04/19/2022 9:51:12 AM

Tuesday, April 19, 2022 9:51:12 AM

Post# of 252187
The REGN-CMPI deal has the second-highest premium among all biotech buyouts since 2008 with a deal value >=$200M, trailing only AGN-TBRA (#msg-168586536).

On the other hand, CMPI’s closing price yesterday was down 81% from its 2020 IPO (#msg-157450928), so even the 336% premium being paid by REGN amounts to a substantial discount from the IPO price.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up